季节性冠状病毒感染个体中 SARS-CoV-2 感染和 COVID-19 严重程度。
SARS-CoV-2 infection and COVID-19 severity in individuals with prior seasonal coronavirus infection.
机构信息
Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Department of Biomedical Informatics and Medical Education, University of Washington School of Medicine, Seattle, WA, USA.
出版信息
Diagn Microbiol Infect Dis. 2021 Jun;100(2):115338. doi: 10.1016/j.diagmicrobio.2021.115338. Epub 2021 Feb 9.
Abstract
We show that individuals with documented history of seasonal coronavirus have a similar SARS-CoV-2 infection rate and COVID-19 severity as those with no prior history of seasonal coronavirus. Our findings suggest prior infection with seasonal coronavirus does not provide immunity to subsequent infection with SARS-CoV-2.
摘要
我们的研究表明，有季节性冠状病毒病史的个体与没有季节性冠状病毒病史的个体 SARS-CoV-2 感染率和 COVID-19 严重程度相似。我们的研究结果表明，先前感染季节性冠状病毒并不能为随后感染 SARS-CoV-2 提供免疫力。
相似文献
1
SARS-CoV-2 infection and COVID-19 severity in individuals with prior seasonal coronavirus infection.季节性冠状病毒感染个体中 SARS-CoV-2 感染和 COVID-19 严重程度。
Diagn Microbiol Infect Dis. 2021 Jun;100(2):115338. doi: 10.1016/j.diagmicrobio.2021.115338. Epub 2021 Feb 9.
2
Antibodies to Seasonal Coronaviruses Rarely Cross-React With SARS-CoV-2: Findings From an African Birth Cohort.季节性冠状病毒抗体与 SARS-CoV-2 很少发生交叉反应：来自非洲出生队列的研究结果。
Pediatr Infect Dis J. 2021 Dec 1;40(12):e516-e519. doi: 10.1097/INF.0000000000003325.
3
Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses.与季节性冠状病毒预先存在的免疫有关的 SARS-CoV-2 易感性增加和 COVID-19 严重程度的证据。
Cell Rep. 2021 Dec 28;37(13):110169. doi: 10.1016/j.celrep.2021.110169. Epub 2021 Dec 7.
4
Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.具有有限的新冠病毒交叉反应性的季节性冠状病毒特异性B细胞在重症新冠病毒肺炎中主导IgG反应。
J Clin Invest. 2021 Nov 1;131(21). doi: 10.1172/JCI150613.
5
Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses.密歇根家庭流感疫苗评估（HIVE）队列中冠状病毒的发生：再感染频率和对季节性和严重急性呼吸综合征冠状病毒的血清学反应。
J Infect Dis. 2021 Jul 2;224(1):49-59. doi: 10.1093/infdis/jiab161.
6
Potential impact of individual exposure histories to endemic human coronaviruses on age-dependent severity of COVID-19.个体暴露于地方性人类冠状病毒史对 COVID-19 年龄相关严重程度的潜在影响。
BMC Med. 2021 Jan 12;19(1):19. doi: 10.1186/s12916-020-01887-1.
7
Limited Recognition of Highly Conserved Regions of SARS-CoV-2.有限识别 SARS-CoV-2 的高度保守区域。
Microbiol Spectr. 2022 Feb 23;10(1):e0278021. doi: 10.1128/spectrum.02780-21.
8
Prior presumed coronavirus infection reduces COVID-19 risk: A cohort study.既往疑似冠状病毒感染降低 COVID-19 风险：一项队列研究。
J Infect. 2020 Dec;81(6):923-930. doi: 10.1016/j.jinf.2020.10.023. Epub 2020 Oct 27.
9
Seasonal coronavirus protective immunity is short-lasting.季节性冠状病毒的保护免疫作用是短暂的。
Nat Med. 2020 Nov;26(11):1691-1693. doi: 10.1038/s41591-020-1083-1. Epub 2020 Sep 14.
10
Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination.季节性冠状病毒刺突蛋白免疫不能预防小鼠模型中 SARS-CoV-2 的挑战，但对 COVID-19 mRNA 疫苗接种介导的保护没有不利影响。
J Virol. 2023 Mar 30;97(3):e0166422. doi: 10.1128/jvi.01664-22. Epub 2023 Feb 13.
引用本文的文献
1
Differential patterns of antibody response against SARS-CoV-2 nucleocapsid epitopes detected in sera from patients in the acute phase of COVID-19, convalescents, and pre-pandemic individuals.在 COVID-19 急性期患者、恢复期患者和大流行前个体的血清中检测到针对 SARS-CoV-2 核衣壳表位的抗体反应的差异模式。
Pathog Dis. 2024 Feb 7;82. doi: 10.1093/femspd/ftae025.
2
Does Prior Respiratory Viral Infection Provide Cross-Protection Against Subsequent Respiratory Viral Infections? A Systematic Review and Meta-Analysis.先前的呼吸道病毒感染是否能提供针对随后的呼吸道病毒感染的交叉保护作用？系统评价和荟萃分析。
Viruses. 2024 Jun 19;16(6):982. doi: 10.3390/v16060982.
3
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents.血清人冠状病毒刺突蛋白特异性抗体不能预防儿童和青少年后续感染新型冠状病毒。
iScience. 2023 Nov 21;26(12):108500. doi: 10.1016/j.isci.2023.108500. eCollection 2023 Dec 15.
4
The role of cross-reactive immunity to emerging coronaviruses: Implications for novel universal mucosal vaccine design.新兴冠状病毒交叉反应性免疫的作用：对新型通用黏膜疫苗设计的启示。
Saudi Med J. 2023 Oct;44(10):965-972. doi: 10.15537/smj.2023.44.10.20230375.
5
Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies.解析针对冠状病毒世界的抗原交叉反应：共享表位的稳定性程度及SARS-CoV-2抗刺突交叉中和抗体
Pathogens. 2023 May 13;12(5):713. doi: 10.3390/pathogens12050713.
6
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors.严重 COVID-19 的风险因素：宿主、病毒和环境因素的综述。
Viruses. 2023 Jan 7;15(1):175. doi: 10.3390/v15010175.
7
Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms.三种不同新冠疫苗平台诱导的针对新冠病毒变异株以及季节性人类冠状病毒NL63、HKU1和229E的抗体中和活性分析
Vaccines (Basel). 2022 Dec 27;11(1):58. doi: 10.3390/vaccines11010058.
8
Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Central and West African Populations.大流行前中非人群对 SARS-CoV-2 的交叉反应性免疫。
Viruses. 2022 Oct 14;14(10):2259. doi: 10.3390/v14102259.
9
Knowledge of SARS-CoV-2 Epitopes and Population HLA Types Is Important in the Design of COVID-19 Vaccines.了解严重急性呼吸综合征冠状病毒2（SARS-CoV-2）表位和人群人类白细胞抗原（HLA）类型对2019冠状病毒病（COVID-19）疫苗设计至关重要。
Vaccines (Basel). 2022 Sep 24;10(10):1606. doi: 10.3390/vaccines10101606.
10
Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination.mRNA COVID-19 疫苗接种后 ICU 工作人员中 SARS-CoV-2 特异性 T 细胞反应的差异。
Front Immunol. 2022 Oct 6;13:942192. doi: 10.3389/fimmu.2022.942192. eCollection 2022.
本文引用的文献
1
Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4 T Cells in COVID-19.COVID-19 中 SARS-CoV-2 反应性调节性和细胞毒性 CD4 T 细胞的失衡。
Cell. 2020 Nov 25;183(5):1340-1353.e16. doi: 10.1016/j.cell.2020.10.001. Epub 2020 Oct 5.
2
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.未暴露于 SARS-CoV-2 人群中的选择性和交叉反应性 T 细胞表位。
Science. 2020 Oct 2;370(6512):89-94. doi: 10.1126/science.abd3871. Epub 2020 Aug 4.
3
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.SARS-CoV-2 反应性 T 细胞在健康供体和 COVID-19 患者中的研究。
Nature. 2020 Nov;587(7833):270-274. doi: 10.1038/s41586-020-2598-9. Epub 2020 Jul 29.
4
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.COVID-19 和 SARS 病例以及未感染对照者的 SARS-CoV-2 特异性 T 细胞免疫。
Nature. 2020 Aug;584(7821):457-462. doi: 10.1038/s41586-020-2550-z. Epub 2020 Jul 15.
5
Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.急性呼吸窘迫综合征的 COVID-19 患者中 SARS-CoV-2 特异性 T 细胞的表型和动力学。
Sci Immunol. 2020 Jun 26;5(48). doi: 10.1126/sciimmunol.abd2071.
6
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.COVID-19 疾病患者和未接触者体内针对 SARS-CoV-2 冠状病毒的 T 细胞反应的靶标。
Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20.
Zotero 插件